RT Journal Article
SR Electronic
T1 Spatial Allocation of Scarce COVID-19 Vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.18.20248439
DO 10.1101/2020.12.18.20248439
A1 Castonguay, François M.
A1 Blackwood, Julie C.
A1 Howerton, Emily
A1 Shea, Katriona
A1 Sims, Charles
A1 Sanchirico, James N.
YR 2021
UL http://medrxiv.org/content/early/2021/03/14/2020.12.18.20248439.abstract
AB Although the COVID-19 disease burden is heterogeneous across space, the U.S. National Academies of Sciences, Engineering, and Medicine recommends an equitable spatial allocation of vaccines based, for example, on population size, in the interest of speed and workability. Utilizing economic–epidemiological modeling, we benchmark the performance of this ad hoc allocation rule by comparing it to the rule that minimizes the economic damages and expenditures over time, including a penalty cost representing the social costs of deviating from ad hoc allocations that favor speed and workability. Under different levels of vaccine scarcity and different demographic characteristics, we consider scenarios where length of immunity and compliance to travel restrictions vary, and consider the robustness of the rules when assumptions regarding these factors are incorrect. The benefits from deviating are especially high when immunity is permanent, when there is compliance to travel restrictions, when the supply of vaccine is low, and when there is heterogeneity in demographic characteristics. Interestingly, a lack of compliance to travel restrictions pushes the optimal allocations of vaccine towards the ad hoc and improves the relative robustness of the ad hoc rules, as the mixing of the populations reduces the spatial heterogeneity in disease burden.JEL Classification C61, H12, H84, I18, Q54Competing Interest StatementThe authors have declared no competing interest.Funding StatementF.M.C. acknowledges funding from the Henry A. Jastro Graduate Research Scholarship Award. K.S and E.H. acknowledge funding from the Huck Institutes for the Life Sciences at The Pennsylvania State University. J.N.S. is a member of the Giannini Foundation of Agricultural Economics and acknowledges support from National Institute of Food and Agriculture (CA-D-ESP-7853-H).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No human or animal subjects were involved in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe parameter values used to run the numerical simulations are publicly available from the citations included in the text. https://github.com/fmcastonguay/SpatialAllocationCOVID19